The record
| Class | triple agonist |
|---|---|
| Also known as | LY3437943 |
| Chain length | - |
| Molecular weight | 4,731.33 Da |
| Half-life | ≈6 days (reported in clinical PK summaries/reviews; supports once-weekly dosing) |
| Route | Subcutaneous (SC) in clinical trials |
| Studied for | Investigational for obesity/chronic weight management and metabolic disease (including type 2 diabetes). |
| Research use | Metabolic research (energy balance, appetite, glucose control) and mechanistic studies (e.g., gastric emptying, incretin/glucagon receptor pharmacology). |
| What has been shown | Dose-dependent, clinically meaningful weight loss reported in a phase 2 obesity trial (highest studied maintenance dose 12 mg once weekly, SC).; Metabolic improvements consistent with incretin/glucagon multi-agonism (reported across early clinical development literature). |
| How it works | Investigational "triple agonist" that activates GLP-1, GIP, and glucagon receptors, aiming to reduce appetite/food intake, improve glycemic control, and increase energy expenditure. |
| Patent status | patented (assumed for an active investigational asset; verify per jurisdiction if needed) |
| Regulatory status | investigational / clinical-stage |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Fat Loss Signaling Environment (affection, 39%)
- Glucose Regulation Support (affection, 62%)
- Appetite Regulation Environment (affection, 84%)
- Cardiovascular risk reduction in T2DM (illness, 30%)
- CV risk reduction in T2D with CVD (illness, 40%)
- Fat loss without muscle loss (illness, 30%)
- Investigational for obesity/chronic weight management and metabolic disease (illness, 100%)
- NASH/fatty liver (illness, 30%)
- Obesity/weight management (illness, 36%)
- Type 2 diabetes (illness, 40%)
- Type 2 diabetes mellitus (illness, 30%)
- Weight management (illness, 30%)
- Weight gain or constant hunger (symptom, 50%)
- High blood sugar (symptom, 50%)